SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 NGS Genetic DNA Test
Comprehensive Genetic Testing for Neurological Disorders in Infants
The SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 NGS Genetic DNA Test represents a breakthrough in pediatric neurological diagnostics. This advanced genetic screening utilizes state-of-the-art Next-Generation Sequencing technology to identify mutations in the SLC25A22 gene, which plays a critical role in mitochondrial function and brain development. Early infantile epileptic encephalopathy type 3 is a severe neurological condition that typically manifests within the first months of life, characterized by intractable seizures, developmental regression, and significant neurological impairment.
What This Test Measures and Detects
Our comprehensive genetic analysis specifically targets:
- Mutations in the SLC25A22 gene encoding the mitochondrial glutamate carrier
- Pathogenic variants associated with early-onset epileptic encephalopathy
- Genetic markers for mitochondrial dysfunction in neurological development
- Inheritance patterns and carrier status information
- Specific nucleotide changes affecting mitochondrial transport mechanisms
Who Should Consider This Genetic Test
This specialized genetic testing is recommended for infants and children presenting with:
- Early-onset seizures within the first 3 months of life
- Developmental regression or stagnation
- Abnormal EEG patterns consistent with epileptic encephalopathy
- Family history of similar neurological conditions
- Unexplained neurological symptoms in infancy
- Hypotonia (reduced muscle tone) and movement disorders
- Feeding difficulties and failure to thrive
Significant Benefits of Genetic Testing
Early genetic diagnosis through our SLC25A22 testing provides numerous advantages:
- Accurate diagnosis enabling targeted treatment strategies
- Early intervention opportunities for better developmental outcomes
- Comprehensive genetic counseling for family planning
- Elimination of diagnostic uncertainty and unnecessary testing
- Personalized medical management based on genetic findings
- Improved understanding of disease progression and prognosis
- Access to specialized neurological care and support services
Understanding Your Test Results
Our genetic specialists provide comprehensive result interpretation:
- Positive Result: Indicates the presence of pathogenic SLC25A22 mutations, confirming the diagnosis of early infantile epileptic encephalopathy type 3
- Negative Result: Suggests that SLC25A22 mutations are not detected, though other genetic causes should be considered
- Variant of Uncertain Significance: Requires additional family studies and clinical correlation
- Carrier Status: Identifies individuals who carry one copy of the mutation without showing symptoms
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| Discount Price | $500 |
| Regular Price | $700 |
Nationwide Testing Availability
We have established testing facilities across major metropolitan areas throughout the United States, including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified genetic counselors and neurological specialists ensures comprehensive care coordination regardless of your location.
Take Action Today
Don’t let diagnostic uncertainty delay crucial medical interventions. Early genetic testing can provide the answers needed to guide appropriate treatment and support for affected infants. Our team of genetic specialists and neurological experts are ready to assist you through every step of the testing process.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic consultation and testing appointment. Early diagnosis leads to better outcomes – take the first step toward understanding your child’s neurological health.
